Harmony Biosciences (HRMY) Q2 2026 earnings review
Record Revenues & Massive Operating Leverage Marred by Abrupt CFO Exit
Harmony delivered an exceptionally strong Q2, posting a record $261.3M in WAKIX revenue (+30% YoY) and putting the Q1 seasonal growth scare firmly in the rearview mirror. Net patient additions rebounded sharply to 450, validating underlying demand. Bottom-line performance was equally impressive, with Net Income surging 90% YoY to $75.4M, driven by stringent operating expense control that fully offset a 520-bps gross margin compression caused by new licensing royalties. However, the unexpected departure of CFO Glenn Reicin—just three months after his appointment—raises serious execution questions, especially as management aggressively touts a $962M war chest meant for imminent business development.
🐂 Bull Case
WAKIX net patient additions accelerated to 450 (up from 100 in Q1), bringing the total to 8,950 average patients and proving that Q1's sluggishness was purely seasonal access friction, not market saturation.
Phase 1 SAD data for the Orexin-2 agonist BP-205 confirmed a best-in-class pharmacokinetic profile (30-75 min Tmax and ~25h half-life), allowing for ideal once-daily dosing potential.
🐻 Bear Case
The abrupt resignation of CFO Glenn Reicin in July, immediately following his April appointment, is a major red flag for a company explicitly claiming 'urgency' to deploy nearly $1B in M&A capital.
Cost of goods sold jumped to 24.2% of net revenues from 19.0% a year ago, permanently dragging gross margins down due to the newly attached Novitium royalty obligations.
⚖️ Verdict: 🟢
Bullish. The core commercial franchise is printing cash, and the pipeline readouts are highly encouraging. If management can execute its BD strategy despite the C-suite shuffle, the path to sustained value creation is clear.
Key Themes
WAKIX Volume Rebounds From Seasonal Lows
The narrative that Q1's anemic net patient additions (+100) were a one-off seasonal insurance reset issue was entirely vindicated. Q2 saw WAKIX average patients climb by 450 to 8,950. This represents the second-highest quarterly patient addition in the drug's 7-year commercial history, driving 30% YoY revenue growth and proving the efficacy of the recent 20% field force expansion. The macro headwinds of Q1 plan changes have fully subsided.
BP-205 De-Risks Orexin-2 Pipeline Value
Harmony unveiled highly anticipated Phase 1 Single Ascending Dose (SAD) data for its Orexin-2 agonist BP-205, strongly backing claims of a potential 'best-in-class' profile. The data revealed rapid absorption (Tmax 30-75 mins) alongside a 25-hour mean half-life. This thread-the-needle PK profile means the drug can trigger rapid wakefulness while maintaining efficacy throughout the day on a highly convenient once-daily oral dosing schedule. With extreme potency and over 600x selectivity for OX2R over OX1R, Harmony is aggressively initiating Phase 2 trials for multiple CNS indications by mid-2027.
Massive Operating Leverage Masks Gross Margin Hit
Despite a massive top-line surge, total operating expenses actually fell 5% YoY to $108.8M. G&A expenses dropped 17% (due to a non-repeating prior-year ANDA settlement charge) and R&D fell 7% (due to a prior-year $15M milestone payment). This aggressive OPEX control allowed operating income to scale 85% YoY. This operational leverage is vital, as it completely overshadowed a simultaneous compression in Gross Margins.
COGS Jump Contradicts Flawless P&L Narrative
While net income nearly doubled, the underlying unit economics degraded. Cost of Product Sold (COGS) ballooned 66% YoY to $63.2M, compressing Gross Margin from 81.0% to 75.8%. Management attributed this to new royalties related to the Q1 Novitium license agreement. This creates a permanent structural drag on gross profitability moving forward, meaning future earnings growth will require continued strict limits on R&D and SG&A.
Abrupt CFO Departure Creates Strategic Void
Glenn Reicin stepped down as CFO on July 16, 2026, mere months after his appointment in Q1. While the company stated this was 'not the result of any disagreement', abrupt C-suite turnover is a significant concern. Harmony's stated strategic priority is an 'urgency to deploy capital' for business development, leveraging their $962M cash pile. Executing transformative M&A without a permanent CFO introduces elevated transaction and execution risks.
Lingering IP Litigation Overhang
While Harmony has settled with 6 of the 7 generic ANDA filers to secure exclusivity until March 2030, the final holdout (AET Pharma) remains an active threat. The bench trial for the primary patents ('197 and '947) has concluded, and closing arguments are scheduled for October 22, 2026. A separate lawsuit regarding the amorphous form ('920) was just launched. Until the judge rules, catastrophic generic entry risk remains non-zero.
Other KPIs
Accelerating. Up from $870.5M in Q1 and $882.5M at the end of FY25. Harmony generated robust free cash flow in the quarter, swelling its war chest. Management has explicitly earmarked this capital for strategic business development, targeting late-stage assets to fill the 2028-2032 revenue gap before WAKIX loses exclusivity.
Accelerating. Increased 13% YoY from $30.1M. This reflects the full deployment of the ~20% expansion in field sales and remote sales teams initiated earlier in the year. The investment is clearly bearing fruit, directly correlating with the record WAKIX sales and rebound in patient additions.
Guidance
Stable. Management reiterated their full-year guidance. At the $1.02B midpoint, this implies approximately 17.4% YoY growth from FY25's $869M. Reaching the $1 billion blockbuster threshold is a critical psychological milestone for the franchise, and strong Q2 outperformance significantly de-risks this target.
Key Questions
CFO Turnover and BD Execution
With the sudden departure of the CFO just months into the role, how has the internal process for evaluating and structuring M&A deals changed, and does this delay your timeline for deploying the $962M cash balance?
BP-205 MAD Trial Side Effects
You acknowledged seeing transient, on-target side effects like insomnia and polyuria in the 15-day Multiple Ascending Dose (MAD) study. Can you quantify the incidence rates of these events compared to placebo, and how does the team plan to mitigate them structurally before Phase 2?
Gross Margin Run-Rate
Cost of goods sold leaped to 24.2% of revenues due to Novitium royalties. Is this 24-25% range the new structural baseline for COGS, or are there volume-based tiers that will allow gross margins to recover over time?
ANDA Litigation Scenarios
With closing arguments for the AET bench trial scheduled for October, what contingency plans are in place regarding commercial strategy and capital preservation if the judge issues an adverse ruling allowing a generic launch prior to 2030?